BC-CfE researchers examine a novel antiviral compound discovery

Dr. Peter Cheung, a staff scientist in the BC-CfE laboratory, recently published a paper as a co-first author on the topic of a novel antiviral compound discovery.Dr. Cheung worked with researchers at the University of BC and the University of Toronto to characterize chemical compounds that inhibit HIV in novel ways compared to antiretroviral agents currently used. Specifically, the molecules discussed in the paper “2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing” impact the processing and production of mRNA “messages” that instruct a cell to make proteins.

Read More »

BC-CfE research advances understanding of dynamics within HIV transmission clusters

Understanding the dynamics within HIV transmission clusters is critical information that can help prioritize public health resource allocation. Although HIV sequence clustering is routinely used to identify subpopulations experiencing elevated transmission, there’s a risk of over-simplifying transmission dynamics within clusters as well as the risk that clustering methodology influences outcomes.

Read More »

Change of Leadership for BC-CfE’s Clinical Education and Training Program

The BC-CfE’s Clinical Education and Training Program recently saw a change in leadership from Dr. Silvia Guillemi, who started leading the program when it began back in 2011, to Dr. Val Montessori. Dr. Montessori has multiple roles, as she will be leading the Clinical Education and Training Program while also serving as the Head of the Division of Infectious Diseases at St. Paul’s Hospital and as the Co-chair of the Committee for Drug Evaluation and Therapy. Dr. Montessori also works as a Clinical Associate professor in the Division of Infectious Diseases at the University of British Columbia. The Clinical Education and Training Program was designed to provide learning opportunities on the diagnosis, treatment, management and care of HIV/AIDS and related conditions through personalized learning programs.

Read More »
Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below